tacedinaline: oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tacedinaline : A benzamide obtained by formal condensation of the carboxy group of 4-acetamidobenzoic acid with one of the amino groups of 1,2-phenylenediamine. An oral cytostatic drug with impressive differential activity against leukemic cells and normal stem-cells. Also used in combination therapy for selected tumors including non-smoll cell lung, pancreatic, breast, and colorectal cancers. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 2746 |
| CHEMBL ID | 235191 |
| CHEBI ID | 90195 |
| SCHEMBL ID | 144794 |
| MeSH ID | M0218374 |
| Synonym |
|---|
| tacedinaline |
| pd-123654 |
| goe-5549 |
| ci-994 |
| acetyldinaline |
| ci 994 , |
| 4-(acetylamino)-n-(2-aminophenyl)benzamide |
| pd 123654 |
| goe 5549 |
| tacedinalina |
| benzamide, 4-(acetylamino)-n-(2-aminophenyl)- |
| tacedinalina [inn-spanish] |
| tacedinaline [usan:inn] |
| c.i. 994 |
| 4-acetylamino-n-(2'-aminophenyl)benzamide |
| D05988 |
| tacedinaline (usan/inn) |
| 112522-64-2 |
| n-acetyldinaline |
| n-(2-aminophenyl)-4-acetamidobenzamide |
| bdbm19422 |
| CHEMBL235191 |
| chebi:90195 , |
| EC-000.2116 |
| FT-0650475 |
| VAZAPHZUAVEOMC-UHFFFAOYSA-N |
| 4-acetamino-n-(2'-aminophenyl)-benzamide |
| 4-acetamido-n-(2-aminophenyl)benzamide |
| BCP9000527 |
| unii-umf554n5fg |
| umf554n5fg , |
| BRD-K52313696-001-01-6 |
| HY-50934 |
| CS-1280 |
| BCPP000281 |
| AKOS015890391 |
| S2818 |
| ci994 (tacedinaline) |
| CCG-208757 |
| MLS006010120 |
| smr002530306 |
| SCHEMBL144794 |
| tacedinaline [who-dd] |
| tacedinaline [inn] |
| tacedinaline [usan] |
| pd123654 , |
| HB1385 |
| 4-(acetylamino)-n-(2-aminophenyl)be nzamide |
| gtpl8367 |
| ci994 |
| AC-32996 |
| mfcd00866266 |
| DTXSID60150095 |
| J-002788 |
| ci-994, >=98% (hplc), powder |
| EX-A224 |
| sr-01000944935 |
| SR-01000944935-1 |
| HMS3651P13 |
| NCGC00263639-02 |
| SW219372-1 |
| DB12291 |
| tacedinaline (ci-994) |
| Q27088920 |
| AS-19557 |
| BCP02577 |
| BRD-K52313696-001-08-1 |
| acetyldinaline, tacedinaline |
| F11454 |
| 4-acetylamino-n-(2-aminophenyl)benzamide |
| EN300-657160 |
| tacedinaline (ci994) |
| SY055269 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following treatment mice were evaluated for pharmacodynamic effects as well as the pharmacokinetic behavior of CI-994 and the de-acetylated derivative dinaline." | ( Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). Corbett, TH; Foster, BJ; Jones, L; LoRusso, PM; Wiegand, R, 1997) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule." | ( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017) | 0.46 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " To characterize the effects of CI-994 on lymphoid tissue, male rats were administered single oral doses at 0 (vehicle control), 10, 23, and 45 mg/kg and killed up to 7 days after dosing for evaluation of white blood cell differentials, bone marrow differentials, lymphoid tissue weights, and selected histopathology of lymphoid tissue." | ( Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue. Galati, AJ; Graziano, MJ; Walsh, KM, ) | 0.13 |
| " There are several strategies for increasing dose intensity, one being a protracted daily dosing strategy without major dose reduction for toxicity." | ( Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond. Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE, 2000) | 0.31 |
| " Dosage escalation proceeded in 2 phases; an Acute Dosing Phase (n = 11) to define the MTD for CI-994 administered over 2 weeks and a Chronic Dosing Phase (n = 29) to define the MTD for daily administration for 8 weeks." | ( Chronic oral administration of CI-994: a phase 1 study. Flaherty, L; Foster, BJ; Heilbrun, LK; LoRusso, PM; Meyer, M; Prakash, S; Radulovic, L; Valdivieso, M; Wozniak, A; Zalupski, M, 2001) | 0.31 |
| " For the in vivo study, BDF(1) mice were dosed orally with 50 mg/kg acetyldinaline every day for 14 days." | ( In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Foster, BJ; LoRusso, PM; Parchment, RE; Volpe, DA, 2004) | 0.32 |
| " In the in vivo experiments, platelet counts decreased throughout the 14-day dosing period and had returned to normal by day 18." | ( In vitro and in vivo effects of acetyldinaline on murine megakaryocytopoiesis. Foster, BJ; LoRusso, PM; Parchment, RE; Volpe, DA, 2004) | 0.32 |
| "Fifty-four patients were treated according to three different dosing schemes in which the capecitabine dose was fixed and the CI-994 dose was escalated." | ( A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) | 0.32 |
| "Our research provided evidence supporting the lower-dose RTX strategy in treating NMOSD and reopened the issues of optimal dosage and therapy initiation timing." | ( Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study. Bai, M; Guo, J; Lei, T; Li, H; Li, Z; Liu, Z; Lu, J; Ma, C; Ren, K; Wu, J; Wu, S; Xu, Z; Zhao, D; Zhao, S, 2023) | 0.91 |
| Role | Description |
|---|---|
| EC 3.5.1.98 (histone deacetylase) inhibitor | An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98). |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| benzamides | |
| substituted aniline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 5.2300 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 5.2300 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | IC50 (µMol) | 20.7165 | 0.0004 | 0.6196 | 10.0000 | AID1266094; AID1401901; AID1596080; AID1598961; AID1598982; AID1602240; AID1706053; AID1797850; AID1801572; AID303016; AID303018 |
| Histone deacetylase 3 | Homo sapiens (human) | Ki | 0.2088 | 0.0002 | 0.4237 | 8.1900 | AID1801572; AID496803 |
| Nuclear receptor corepressor 1 | Homo sapiens (human) | IC50 (µMol) | 32.0000 | 0.0098 | 0.0741 | 0.2340 | AID1598961 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0000 | 2.3983 | 10.0000 | AID1401904 |
| Nicotinamide phosphoribosyltransferase | Homo sapiens (human) | IC50 (µMol) | 2.0000 | 0.0001 | 0.0710 | 2.1000 | AID1451820 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 (µMol) | 23.2175 | 0.0006 | 1.0526 | 10.0000 | AID1401901; AID1596080; AID1598982; AID1801572; AID303018 |
| Histone deacetylase 4 | Homo sapiens (human) | Ki | 0.0950 | 0.0002 | 1.6255 | 9.1242 | AID1801572 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 11.8000 | 0.0001 | 0.5543 | 9.9000 | AID1266092; AID1361627; AID1401901; AID1401902; AID1451821; AID1451854; AID1466000; AID1596049; AID1596080; AID1598964; AID1598982; AID1602238; AID1706051; AID1797850; AID1801572; AID303014; AID303018; AID320808 |
| Histone deacetylase 1 | Homo sapiens (human) | Ki | 0.0838 | 0.0000 | 0.4988 | 8.1900 | AID1801572; AID496801 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 (µMol) | 23.2175 | 0.0007 | 1.0260 | 9.9000 | AID1401901; AID1596080; AID1598982; AID1801572; AID303018 |
| Histone deacetylase 7 | Homo sapiens (human) | Ki | 0.0950 | 0.0002 | 2.0005 | 9.5000 | AID1801572 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 (µMol) | 13.0657 | 0.0001 | 0.7221 | 9.9700 | AID1266093; AID1401901; AID1401903; AID1466001; AID1596050; AID1596080; AID1598963; AID1598982; AID1602239; AID1706052; AID1797850; AID1801572; AID303015; AID303018 |
| Histone deacetylase 2 | Homo sapiens (human) | Ki | 0.1188 | 0.0000 | 0.4709 | 8.1900 | AID1801572; AID496802 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 (µMol) | 3.0525 | 0.0005 | 0.7245 | 9.9000 | AID1401901; AID1596080; AID1598982; AID303018 |
| Histone deacetylase 11 | Homo sapiens (human) | IC50 (µMol) | 3.0525 | 0.0003 | 0.9298 | 9.9000 | AID1401901; AID1596080; AID1598982; AID303018 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 (µMol) | 19.6450 | 0.0007 | 0.9947 | 9.9000 | AID1401901; AID1596080; AID1598962; AID1598982; AID1797850; AID1801572; AID303017; AID303018 |
| Histone deacetylase 8 | Homo sapiens (human) | Ki | 0.0950 | 0.0002 | 0.7525 | 8.1900 | AID1801572 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 (µMol) | 31.2124 | 0.0000 | 0.5376 | 9.9000 | AID1266095; AID1401901; AID1401904; AID1466002; AID1596034; AID1596080; AID1598981; AID1598982; AID1801572; AID303018 |
| Histone deacetylase 6 | Homo sapiens (human) | Ki | 0.0950 | 0.0001 | 0.4156 | 8.1900 | AID1801572 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 (µMol) | 23.2175 | 0.0005 | 0.9413 | 9.9000 | AID1401901; AID1596080; AID1598982; AID1801572; AID303018 |
| Histone deacetylase 9 | Homo sapiens (human) | Ki | 0.0950 | 0.0002 | 1.8520 | 9.0000 | AID1801572 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 (µMol) | 23.2175 | 0.0007 | 0.9610 | 10.0000 | AID1401901; AID1596080; AID1598982; AID1801572; AID303018 |
| Histone deacetylase 5 | Homo sapiens (human) | Ki | 0.0950 | 0.0002 | 1.2993 | 9.5000 | AID1801572 |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | IC50 (µMol) | 0.1900 | 0.0017 | 0.5952 | 8.0000 | AID1706053 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 1.8512 | 6.7000 | AID1599722 |
| Histone deacetylase 4 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.3523 | 6.7000 | AID1599722 |
| Histone deacetylase 1 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 1.9877 | 6.7000 | AID1599722 |
| Histone deacetylase 7 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.3211 | 6.7000 | AID1599722 |
| Histone deacetylase 2 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 1.8575 | 6.7000 | AID1599722 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.5465 | 6.7000 | AID1599722 |
| Histone deacetylase 11 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.5465 | 6.7000 | AID1599722 |
| Histone deacetylase 8 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.2734 | 6.7000 | AID1599722 |
| Histone deacetylase 6 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0052 | 1.5998 | 6.7000 | AID1599722 |
| Histone deacetylase 9 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.3266 | 6.7000 | AID1599722 |
| Histone deacetylase 5 | Homo sapiens (human) | EC50 (µMol) | 3.8100 | 0.0300 | 2.5465 | 6.7000 | AID1599722 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1801572 | In-vitro HDAC Enzymatic Endpoint Assay from Article 10.1021/acschembio.5b00640: \\An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in u00DF-Cell Protection.\\ | 2016 | ACS chemical biology, Feb-19, Volume: 11, Issue:2 | An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. |
| AID1797850 | HDAC Enzyme Activity Assay from Article 10.1021/jm701079h: \\Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.\\ | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1361626 | Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID1466001 | Inhibition of human recombinant HDAC2 using Fluor de Lys green as substrate by fluorometric assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1596034 | Inhibition of human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1266095 | Inhibition of HDAC6 (unknown origin) by fluorimetric assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1401894 | Antiproliferative activity against human HeLa cells at 8 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1465994 | Inhibition of HDAC in human HeLa cell nuclear extract at 0.625 uM using Fluor de Lys green as substrate after 5 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1823326 | Protac activity at VHL/HDAC1 in human HCT-116 cells assessed as reduction in SIN3A level at 10 uM measured after 48 hrs by Western blot analysis | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1598962 | Inhibition of recombinant human HDAC8 assessed as decrease in deacetylation of FLUOR DE LYS substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1412092 | Antiproliferative activity against human H1299 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1466000 | Inhibition of human recombinant HDAC1 using Fluor de Lys as substrate by fluorometric assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID496801 | Inhibition of human HDAC1 | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID1599729 | Cytotoxicity against human A549 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1387553 | Inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM treated for 16 hrs followed by compound washout and measured up to 24 hrs by immunoblot analysis | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1361629 | Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID1466009 | Induction of apoptosis in human A549 cells assessed as necrotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 0.87%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1599000 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598980 | Antiproliferative activity against human HeLa cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1599727 | Cytotoxicity against human Meso13 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1602239 | Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence ass | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides. |
| AID363648 | Aqueous solubility in phosphate buffer at pH 7 | 2008 | Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17 | Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. |
| AID1596080 | Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1676601 | Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1266093 | Inhibition of HDAC2 (unknown origin) by fluorimetric assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1401900 | Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID303021 | Inhibition of HDAC in human HCT116 cells at 60 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1596040 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599015 | Antitumor activity against human A549 cells xenografted in Balb/c nude mouse assessed as decrease in tumor size at 25 mg/kg, ip administered twice per day for 21 days relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1599793 | Inhibition of HDAC6 in human A549 cells assessed as upregulation of p21 mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1598975 | Antiproliferative activity against human HeLa cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1706053 | Inhibition of human recombinant C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-Ac)-AMC as substrate measured after 90 mins by fluor | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID343204 | Growth inhibition of human PC3 cells after 5 days by MTT assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. |
| AID1676599 | Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1596052 | Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1451823 | Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1596071 | Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1401891 | Antiproliferative activity against human A375 cells at 2 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1853061 | PROTAC activity at VHL/HDAC2 in human HCT-116 cells assessed as HDAC2 level incubated for 24 hrs by Western blot analysis relative to control | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. |
| AID1596050 | Inhibition of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS Green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence me | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID303018 | Inhibition of HDAC in 293T cells | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1387566 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of tramadol | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1676594 | Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID343205 | Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay | 2008 | Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13 | Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro. |
| AID1596075 | Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1596036 | Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599787 | Inhibition of HDAC6 in human A549 cells assessed as upregulation of E-cadherin mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1676598 | Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1387536 | Inhibition of human HDAC1 expressed in 293T cells at 100 uM using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay relative to control | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596045 | Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598967 | Antiproliferative activity against human A549 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401901 | Inhibition of HDAC in human HeLa cell extract using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1596066 | Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598961 | Inhibition of recombinant human HDAC3/NCOR1 assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate preincubated for 10 mins followed by substrate addition and and measured after 30 mins by fluorescence based assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1823324 | Induction of apoptosis in human HCT-116 cells assessed as increase in expression of PMAIP1 at 10 uM incubation for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID303024 | Inhibition of human recombinant HDAC3 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1387549 | Inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM measured after 16 hrs by immunoblot analysis | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596051 | Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599724 | Cytotoxicity against human Meso163 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1596078 | Antitumor activity against human A549 cells xenografted in BALB/C mouse assessed as tumor growth inhibition at 25 mg/kg, ip bid for 21 days measured at 3 days interval during compound dosing relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1706050 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell proliferation at 3 uM measured after 24 hrs by MTS assay relative to control | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1676602 | Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1599005 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1823320 | Induction of apoptosis in human HCT-116 cells assessed as downregulation of cyclin El level at 10 uM incubated for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1466007 | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 3.41%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1599790 | Inhibition of HDAC6 in human A549 cells assessed as upregulation of semaphorin 3F mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1853062 | PROTAC activity at VHL/HDAC3 in human HCT-116 cells assessed as HDAC3 level incubated for 24 hrs by Western blot analysis relative to control | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. |
| AID1598991 | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596073 | Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID303016 | Inhibition of human recombinant HDAC3 | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID303015 | Inhibition of human recombinant HDAC2 | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1823319 | Induction of apoptosis in human HCT-116 cells assessed as downregulation of CDK1 level at 10 uM incubated for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1676589 | Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1387572 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of L-carnitine | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1599003 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1599725 | Cytotoxicity against human A549 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1596065 | Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1823325 | Induction of apoptosis in human HCT-116 cells assessed as increase in expression of DHSRS2 at 10 uM incubation for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1676591 | Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID496802 | Inhibition of human HDAC2 | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID1823289 | Inhibition of HDAC2-CoREST-LSD1 (unknown origin) using Boc- (Ac)Lys-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by fluorescent assay | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1387569 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of TEA | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596060 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1465999 | Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 reagent based assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1596037 | Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1676588 | Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1596046 | Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599004 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 2 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1387537 | Inhibition of mouse HDAC6 expressed in 293T cells at 100 uM using Ac-KGLGK(Ac)-MCA as substrate measured after 30 mins by fluorescence assay relative to control | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1401892 | Antiproliferative activity against human A375 cells at 8 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1361627 | Inhibition of human recombinant full length HDAC1 using fluorogenic substrate 3 after 30 mins by fluorescence assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID1401899 | Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1599002 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID363650 | Antiproliferative activity against human NCI-H661 cells after 48 hrs | 2008 | Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17 | Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. |
| AID1412106 | Induction of apoptosis in human A375 cells assessed as late apoptotic cells at 16 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 10.22%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1387565 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of memantine | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596072 | Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID496803 | Inhibition of human HDAC3 | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID320808 | Inhibition of HDAC1 | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). |
| AID1412086 | Induction of DNA damage in human A375 cells assessed as phosphorylation of H2AX at Ser139 residues at 8 uM after 48 hrs relative to control | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1598990 | Induction of apoptosis in human A549 cells assessed as necrotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596047 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1596053 | Inhibition of cell migration in human SMMC7721 cells at 0.5 uM measured after 48 hrs by microscopic analysis | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599014 | Antitumor activity against human A549 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 25 mg/kg, ip administered twice per day for 21 days relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID303020 | Cytotoxicity against human mammary epithelial cells by MTT assay | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1706071 | Increase in LPS/IFNgamma-induced IL6 mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1412103 | Induction of apoptosis in human A375 cells assessed as necrotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 1.64%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1706072 | Increase in LPS/IFNgamma-induced TNFalpha mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1451854 | Inhibition of human recombinant HDAC1 (1 to 482 residues) expressed in Baculovirus using Ac-Leu-Gly-Lys(Ac)-AMC as substrate after 3 hrs by fluorescence assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1401896 | Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1598965 | Induction of apoptosis in human A549 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1387571 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of decynium-22 | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1451821 | Inhibition of human recombinant HDAC1 (1 to 482 residues) expressed in Baculovirus using Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1598971 | Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598999 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G2/M phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.62%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1266094 | Inhibition of HDAC3 (unknown origin) by fluorimetric assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1598979 | Antiproliferative activity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1387563 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of pyrilamine | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID303014 | Inhibition of human recombinant HDAC1 | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1676595 | Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1401890 | Antiproliferative activity against human MGC803 cells at 8 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1401898 | Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1596067 | Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1602238 | Inhibition of recombinant human full length C-terminal His/FALG-tagged HDAC1 expressed in Sf9 insect cells using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides. |
| AID1412102 | Induction of apoptosis in human A375 cells assessed as late apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 10.22%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1596063 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1823317 | Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by cell-titer glo assay | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1823318 | Induction of apoptosis in human HCT-116 cells assessed as downregulation of E2F1 level at 10 uM incubated for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1387570 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of MPP+ | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596043 | Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598988 | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID303027 | Inhibition of human recombinant HDAC5 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1599766 | Inhibition of HDAC6 in human Meso163 cells assessed as increase in histone H3 acetylation at 10 uM measured after 6 to 20 hrs by Western blot analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1596077 | Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599778 | Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of E-cadherin mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1599769 | Inhibition of HDAC6 in human Meso163 cells assessed as alpha tubulin acetylation at 10 uM measured after 6 to 20 hrs by Western blot analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1598985 | Inhibition of HDAC in human A549 cells assessed as increase in histone H3K9 acetylation at 1 uM after 12 hrs by Alexa fluor 488/DAPI staining based laser scanning confocal microscopic analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1412089 | Antiproliferative activity against human A375 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1599730 | Cytotoxicity against human ADCA72 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1387551 | Inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM measured after 6 hrs by immunoblot analysis | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596057 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598989 | Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID303017 | Inhibition of human recombinant HDAC8 | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1676600 | Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1401903 | Inhibition of human recombinant HDAC2 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID303028 | Inhibition of human recombinant HDAC6 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1706070 | Increase in LPS/IFNgamma-induced iNOS mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1598976 | Antiproliferative activity against human A549 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596064 | Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1412109 | Cell cycle arrest in human A375 cells assessed as accumulation at G2/M phase at 8 uM after 72 hrs by propidium iodide/RNase staining based flow cytometric analysis relative to control | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1466003 | Antimigratory activity against human A549 cells at 8 umol/L after 48 hrs by scratch assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1466016 | Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.13%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1412097 | Induction of apoptosis in human A375 cells assessed as early apoptotic cells at 2 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1706069 | Increase in LPS/IFNgamma-induced IL-10 mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1361628 | Inhibition of MDM2 (unknown origin) preincubated for 30 mins by fluorescence polarization assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID1401906 | Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC6 | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1451822 | Cytotoxicity in human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1596055 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1596059 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID303023 | Inhibition of human recombinant HDAC2 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1412095 | Anticlonogenic activity against human A375 cells at 2 to 16 umol/L after 7 days by crystal violet staining based assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1596035 | Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1596056 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1706051 | Inhibition of recombinant human C-terminal His/FLAG-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using Boc-Lys(epsilon-Ac)-AMC as substrate measured after 90 mins by fluorescence assay | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1853026 | Inhibition of class I HDAC in human HCT-116 cells nucleus extract assessed as fold change in H3K56 acetylation level incubated for 24 hrs by Western blot analysis relative to control | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. |
| AID1598982 | Inhibition of HDAC in human HeLa cell nuclear extract assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598998 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1412091 | Antiproliferative activity against human HepG2 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1412099 | Induction of apoptosis in human A375 cells assessed as necrotic cells at 2 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 1.64%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1596048 | Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1466002 | Inhibition of human recombinant HDAC6 using Fluor de Lys as substrate after 60 mins by fluorometric assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1596044 | Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598969 | Antiproliferative activity against human A375 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596062 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1599007 | Antimigratory activity against human A549 cells assessed as reduction in cell migration incubated for 48 hrs by scratch wound healing based microscopic analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID303029 | Inhibition of human recombinant HDAC7 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1598973 | Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 8 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401895 | Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1387564 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of diphenhydramine | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1412107 | Induction of apoptosis in human A375 cells assessed as necrotic cells at 16 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 1.64%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1465995 | Inhibition of HDAC in human HeLa cell nuclear extract at 5 uM using Fluor de Lys green as substrate after 5 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1387573 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of choline | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1598981 | Inhibition of recombinant human His tagged HDAC6 expressed in baculovirus infected insect cells assessed as decrease in deacetylation of FLUOR DE LYS SIRT1 substrate by measuring decrease in fluorescence preincubated for 10 mins followed by substrate addi | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1823321 | Induction of apoptosis in human HCT-116 cells assessed as upregulation of p21 level at 10 uM incubated for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1676590 | Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1598997 | Induction of apoptosis in human A549 cells assessed as necrotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1466020 | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.1%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1412101 | Induction of apoptosis in human A375 cells assessed as early apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1466010 | Induction of apoptosis in human A549 cells assessed as viable cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 92.79%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1823323 | Induction of apoptosis in human HCT-116 cells assessed as increase in expression of TP63 at 10 uM preincubated with HDAC inhibitor incubation for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1598995 | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.19%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1451819 | Induction of apoptosis in human HCT116 cells assessed as early apoptotic cells at 5 uM after 72 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 7.82%) | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1466018 | Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 75.77%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1596039 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1676593 | Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1466015 | Cell cycle arrest in human A549 cells assessed as accumulation at G0/G1 phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 75.77%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1598987 | Induction of apoptosis in human A549 cells assessed as viable cells at 0.5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596038 | Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1412087 | Induction of DNA damage in human A375 cells assessed as phosphorylation of H2AX at Ser139 residues at 16 uM after 48 hrs relative to control | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID303019 | Cytotoxicity against human HCT116 cells by MTT assay | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1596041 | Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598964 | Inhibition of recombinant human His tagged HDAC1 expressed in baculovirus infected insect cells assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by flu | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1387568 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of varenicline | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1823322 | Induction of apoptosis in human HCT-116 cells assessed as upregulation of p15 level at 10 uM incubated for 24 hrs | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1451834 | Induction of apoptosis in human HCT116 cells assessed as late apoptotic cells at 5 uM after 72 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.33%) | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1266085 | Inhibition of human HDAC in HeLa cells nuclear extract at 12.5 uM by fluorimetric assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1598970 | Antiproliferative activity against human SMMC7721 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1599784 | Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of p21 mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1466017 | Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 2 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 9.1%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1599726 | Cytotoxicity against human ADCA72 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1599772 | Inhibition of HDAC6 in human A549 cells assessed as increase in histone H3 acetylation at 10 uM measured after 6 to 20 hrs by Western blot analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1602210 | Dissociation constant, pKa of the compound | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides. |
| AID1387556 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake clearance assessed per mg protein at 4degC measured after 30 mins | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1412105 | Induction of apoptosis in human A375 cells assessed as early apoptotic cells at 16 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1599722 | Inhibition of HDAC in human MeT-5A cells assessed as increase in transfected YFP fused histone H3 acetylation treated at 8 hrs after YFP fused H3 transfection measured after 24 hrs incubation by BRET assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1451824 | Cytotoxicity in human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1465998 | Antiproliferative activity against human HepG2 cells after 72 hrs by CCK-8 reagent based assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1412093 | Antiproliferative activity against human H460 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1596058 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1361630 | Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID1823327 | Protac activity at VHL/HDAC2 in human HCT-116 cells assessed as reduction in SIN3A level at 10 uM measured after 48 hrs by Western blot analysis | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1602240 | Inhibition of recombinant human full length HDAC3 using FAM-labeled acetylated peptide A as substrate preincubated for 3 hrs followed by substrate addition and measured after 60 mins by fluorescence assay | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166 | Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides. |
| AID1451820 | Inhibition of human recombinant NAMPT using NAM as substrate preincubated for 5 mins followed by substrate addition measured after 15 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1266092 | Inhibition of HDAC1 (unknown origin) by fluorimetric assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1466006 | Induction of apoptosis in human A549 cells assessed as viable cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 92.79%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1466019 | Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 16 umol/L after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.13%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1598977 | Antiproliferative activity against human A375 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596061 | Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1466013 | Induction of apoptosis in human A549 cells assessed as necrotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 0.87%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1412090 | Antiproliferative activity against human SMMC7721 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1465997 | Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 reagent based assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1823296 | Inhibition of HDAC3-SMRT (unknown origin) using Boc- (Ac)Lys-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by fluorescent assay | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1596049 | Inhibition of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID363652 | Inhibition of HDAC in human NCI-H661 cells assessed as histone H4 acetylation after 6 hrs by Western blot analysis | 2008 | Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17 | Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. |
| AID1401904 | Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1853060 | PROTAC activity at VHL/HDAC1 in human HCT-116 cells assessed as HDAC1 level incubated for 24 hrs by Western blot analysis relative to control | 2022 | RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12 | A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras. |
| AID1599781 | Inhibition of HDAC6 in human Meso163 cells assessed as upregulation of semaphorin 3F mRNA expression at 10 uM after 24 hrs by RT-Sybr green PCR analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1266091 | Cytotoxicity against human MeT-5A cells | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1596070 | Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1676596 | Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1598963 | Inhibition of recombinant human HDAC2 assessed as decrease in deacetylation of FLUOR DE LYS Green substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence based assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401889 | Antiproliferative activity against human MGC803 cells at 2 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1599008 | Inhibition of colony formation in human A549 cells at 0.5 to 2 uM incubated for 10 to 14 days by crystal violet staining based assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1676597 | Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID1598972 | Antiproliferative activity against human HCT116 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598968 | Antiproliferative activity against human A375 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401897 | Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1465996 | Antiproliferative activity against human A549 cells after 72 hrs by CCK-8 reagent based assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID303026 | Inhibition of human recombinant HDAC4 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1451835 | Induction of apoptosis in human HCT116 cells assessed as necrotic cells at 5 uM after 72 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.25%) | 2017 | Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19 | Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. |
| AID1596042 | Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598978 | Antiproliferative activity against human SMMC7721 cells assessed as decrease in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401902 | Inhibition of human recombinant HDAC1 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1599016 | Toxicity against nude Balb/c mouse xenografted with human A549 cells assessed as no change in body weight at 25 mg/kg, ip administered twice per day for 21 days and measured every 3 days during compound dosing | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598994 | Induction of apoptosis in human A549 cells assessed as viable cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1412088 | Antiproliferative activity against human A549 cells after 72 hrs CCK8 assay | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1823295 | Inhibition of HDAC1-CoREST-LSD1 (unknown origin) using Boc- (Ac)Lys-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr by fluorescent assay | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells. |
| AID1387554 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake clearance assessed per mg protein at 37degC | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1387567 | Substrate activity at PYSOCA in human CMEC/D3 cells assessed as transporter-mediated drug uptake measured for 2 mins at 37degC in presence of clonidine | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1596033 | Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1676592 | Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. |
| AID303025 | Inhibition of human recombinant HDAC8 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1466012 | Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 2.93%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1599723 | Cytotoxicity against human Meso13 cells assessed as cell permeability measured after 72 hrs by CellTox Green assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1599728 | Cytotoxicity against human Meso163 cells assessed as decrease in cell viability measured after 72 hrs by CellTiter-Glo Luminescent assay | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1598992 | Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1466008 | Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 4 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 2.93%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1266087 | Inhibition of HDAC in human MeT-5A cells assessed as hisone H3 acetylation at 10 uM after 16 hrs by BRET assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1 | Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates. |
| AID1412100 | Induction of apoptosis in human A375 cells assessed as viable cells at 2 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 86.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1598966 | Antiproliferative activity against human A549 cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598993 | Induction of apoptosis in human A549 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.135%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1599775 | Inhibition of HDAC6 in human A549 cells assessed as alpha tubulin acetylation at 10 uM measured after 6 to 20 hrs by Western blot analysis | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6 | Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. |
| AID1596068 | Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1412098 | Induction of apoptosis in human A375 cells assessed as late apoptotic cells at 2 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 10.22%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1361631 | Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK8 assay | 2018 | Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16 | Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. |
| AID322414 | Antiproliferative activity against human LNCap by MTT assay | 2008 | Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6 | Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. |
| AID1706052 | Inhibition of recombinant human full-length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-Ac)-AMC as substrate measured after 90 mins by fluorescence assay | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC). |
| AID1401905 | Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6 | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1598983 | Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1598974 | Antiproliferative activity against human HeLa cells assessed as growth inhibition at 2 uM after 72 hrs by CCK-8 assay relative to control | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1387574 | Blood brain barrier permeability in Wistar rat brain at 20 uM by LC-MS/MS analysis | 2018 | ACS medicinal chemistry letters, Sep-13, Volume: 9, Issue:9 | Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors. |
| AID1412104 | Induction of apoptosis in human A375 cells assessed as viable cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 86.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1599001 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at S phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 12.83%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID303022 | Inhibition of human recombinant HDAC1 at 20 uM | 2007 | Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23 | Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. |
| AID1599006 | Antimigratory activity against human A549 cells assessed as reduction in cell migration incubated for 24 hrs by scratch wound healing based microscopic analysis | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1596074 | Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1598996 | Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 2 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.637%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1401893 | Antiproliferative activity against human HeLa cells at 2 uM after 72 hrs by CCK-8 assay relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents. |
| AID1412108 | Induction of apoptosis in human A375 cells assessed as viable cells at 16 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 86.07%) | 2018 | MedChemComm, Feb-01, Volume: 9, Issue:2 | Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties. |
| AID1466011 | Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 8 umol/L after 48 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometry (Rvb = 3.41%) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1596069 | Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%) | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID487229 | Antitumor activity against human HCT116 cells xenografted in mouse at 30 mg/kg | 2010 | European journal of medicinal chemistry, Jun, Volume: 45, Issue:6 | Inside HDAC with HDAC inhibitors. |
| AID1596081 | Inhibition of colony formation in human SMMC7721 cells at 0.25 to 4 uM incubated for 10 days by crystal violet staining based assay | 2019 | European journal of medicinal chemistry, Jul-01, Volume: 173 | Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors. |
| AID1466005 | Inhibition of colony formation in human A549 cells at 2 to 8 umol/L after 7 days by crystal violet staining based assay | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. |
| AID1598984 | Cell cycle arrest in human A549 cells assessed as accumulation of cells at G0/G1 phase at 0.5 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 73.35%) | 2019 | European journal of medicinal chemistry, Aug-15, Volume: 176 | Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508612 | NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3 | Highly predictive and interpretable models for PAMPA permeability. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508591 | NCATS Rat Liver Microsome Stability Profiling | 2020 | Scientific reports, 11-26, Volume: 10, Issue:1 | Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1645848 | NCATS Kinetic Aqueous Solubility Profiling | 2019 | Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14 | Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346082 | Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs)) | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID1346134 | Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs)) | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID1346077 | Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs)) | 2010 | Nature chemical biology, Mar, Volume: 6, Issue:3 | Chemical phylogenetics of histone deacetylases. |
| AID1346134 | Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs)) | 2008 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3 | Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (10.96) | 18.2507 |
| 2000's | 19 (26.03) | 29.6817 |
| 2010's | 29 (39.73) | 24.3611 |
| 2020's | 17 (23.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (6.67%) | 5.53% |
| Reviews | 3 (4.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 67 (89.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||